Trial Profile
A Phase I, Open-Label, Single and Multiple Dose (Twice-Daily), Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation in Healthy Chinese Participants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Aclidinium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 07 Dec 2021 Status changed from active, no longer recruiting to completed.
- 25 Nov 2021 Planned End Date changed from 14 Dec 2021 to 6 Dec 2021.
- 25 Nov 2021 Planned primary completion date changed from 14 Dec 2021 to 6 Dec 2021.